Should I buy or sell Rani Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rani Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RANI shares. View RANI analyst ratings or view top-rated stocks .

What is Rani Therapeutics' stock price target for 2024?

5 analysts have issued 1-year price targets for Rani Therapeutics' stock. Their RANI share price targets range from $8.00 to $17.00. On average, they anticipate the company's stock price to reach $11.50 in the next twelve months. This suggests a possible upside of 65.0% from the stock's current price. View analysts price targets for RANI or view top-rated stocks among Wall Street analysts .

How have RANI shares performed in 2024?

Rani Therapeutics' stock was trading at $3.32 at the beginning of the year. Since then, RANI stock has increased by 109.9% and is now trading at $6.97. View the best growth stocks for 2024 here .

When is Rani Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our RANI earnings forecast .

How were Rani Therapeutics' earnings last quarter?

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) issued its earnings results on Wednesday, March, 20th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.04.

When did Rani Therapeutics IPO?

Rani Therapeutics (RANI) raised $100 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 6,666,667 shares at a price of $14.00-$16.00 per share.

How do I buy shares of Rani Therapeutics?

Shares of RANI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:RANI

Rani Therapeutics (RANI) Stock Price, News & Analysis

→ The 'Smart Money' Is Ready for May 1st Are You? (From Stansberry Research) (Ad)

Free RANI Stock Alerts

$7.07

+1.02 (+16.86%)

(As of 04/19/2024 ET)

Compare

Today's Range: $5.50
▼
$7.20
50-Day Range: $3.03
▼
$7.85
52-Week Range: $1.82
▼
$8.75

Volume: 207,652 shs
Average Volume: 119,548 shs
Market Capitalization: $354.63 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.50

Get Rani Therapeutics alerts:

Rani Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 65.0% Upside
$11.50 Price Target
Short Interest: Bearish
16.70% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.94) to ($0.81) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.90 out of 5 stars

Medical Sector

816th out of 918 stocks

Pharmaceutical Preparations Industry

370th out of 417 stocks

3.5

Analyst's Opinion

Consensus Rating
Rani Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Rani Therapeutics has only been the subject of 3 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
16.70% of the float of Rani Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Rani Therapeutics has a short interest ratio ("days to cover") of 23.7, which indicates bearish sentiment.
Change versus previous month
Short interest in Rani Therapeutics has recently increased by 3.23%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Rani Therapeutics does not currently pay a dividend.
Dividend Growth
Rani Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RANI.

1.1

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 2 news articles for Rani Therapeutics this week, compared to 2 articles on an average week.
Search Interest
13 people have searched for RANI on MarketBeat in the last 30 days. This is an increase of 1,200% compared to the previous 30 days.
MarketBeat Follows
6 people have added Rani Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Rani Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
50.02% of the stock of Rani Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 30.19% of the stock of Rani Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Rani Therapeutics are expected to grow in the coming year, from ($0.94) to ($0.81) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Rani Therapeutics is -5.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Rani Therapeutics is -5.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Rani Therapeutics has a P/B Ratio of 13.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad TradeSmith

The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

Click here to see Louis' new video for yourself.

About Rani Therapeutics Stock (NASDAQ:RANI)

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

RANI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RANI Stock News Headlines

April 18, 2024 | americanbankingnews.com

Rani Therapeutics (NASDAQ:RANI) Trading 14.3% Higher

April 14, 2024 | seekingalpha.com

RANI Rani Therapeutics Holdings, Inc.

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

April 2, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT), Liquidia Technologies (LQDA) and Xtant Medical Holdings (XTNT)

March 25, 2024 | markets.businessinsider.com

Buy Rating for Rani Therapeutics: Promising Clinical Data and Significant Market Potential

March 22, 2024 | seekingalpha.com

Rani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call Transcript

March 21, 2024 | msn.com

RANI: 2023 Results

March 21, 2024 | finance.yahoo.com

Q4 2023 Rani Therapeutics Holdings Inc Earnings Call

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 21, 2024 | finance.yahoo.com

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2023 Earnings Call Transcript

March 20, 2024 | investorplace.com

RANI Stock Earnings: Rani Therapeutics Hldgs Beats EPS for Q4 2023

March 20, 2024 | benzinga.com

Recap: Rani Therapeutics Hldgs Q4 Earnings

March 20, 2024 | globenewswire.com

Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update

March 19, 2024 | benzinga.com

Earnings Outlook For Rani Therapeutics Hldgs

March 16, 2024 | markets.businessinsider.com

Analysts’ Top Healthcare Picks: Verastem (VSTM), Akebia Therapeutics (AKBA)

March 16, 2024 | finance.yahoo.com

RANI Apr 2024 2.500 put

March 15, 2024 | finance.yahoo.com

RANI Apr 2024 5.000 put

March 15, 2024 | globenewswire.com

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

March 13, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Incyte (INCY)

March 12, 2024 | finance.yahoo.com

Individual investors own 40% of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) shares but private companies control 47% of the company

February 22, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Arcus Biosciences (RCUS) and United Therapeutics (UTHR)

February 20, 2024 | finance.yahoo.com

RANI: INITIATION – Realizing Oral Administration of Biologics

February 19, 2024 | bizjournals.com

Silicon Valley businesswomen share thoughts on mentoring

February 6, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Rani Therapeutics Holdings on Strong Clinical and Strategic Prospects

February 6, 2024 | msn.com

Rani Therapeutics Reports Positive Phase 1 Trial Outcomes

February 6, 2024 | msn.com

Rani Therapeutics Shares Exciting Clinical Trial Results

February 6, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Rani Therapeutics on Strong Clinical and Strategic Milestones

See More Headlines

Receive RANI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rani Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/20/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:RANI
CUSIP: N/A
CIK: 1856725
Web: www.ranitherapeutics.com
Phone: 408-457-3700
Fax: N/A
Employees: 140
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $11.50
High Stock Price Target: $17.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +90.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.33)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-33,970,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -79.92%
Return on Assets: -44.08%

Debt

Debt-to-Equity Ratio: 0.96
Current Ratio: 6.36
Quick Ratio: 6.36

Sales & Book Value

Annual Sales: $2.72 million
Price / Sales: 111.57
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.51 per share
Price / Book: 11.86

Miscellaneous

Outstanding Shares: 50,160,000
Free Float: 25,068,000
Market Cap: $303.47 million
Optionable: Optionable
Beta: 0.92

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. Talat Imran (Age 42)
CEO & Director
Comp: $827k
Mr. Svai S. Sanford (Age 54)
Chief Financial Officer
Comp: $661.6k
Dr. Mir Hashim (Age 64)
Chief Scientific Officer
Comp: $661.6k
Mr. Eric Groen (Age 53)
General Counsel
Ms. Bella Vazquez
Vice President of Human Resources
Ms. Kate McKinley M.B.A.
Chief Business Officer
Ms. Arvinder Dhalla
Vice President of Clinical Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RANI Stock Analysis - Frequently Asked Questions

Should I buy or sell Rani Therapeutics stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rani Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RANI shares.
View RANI analyst ratings or view top-rated stocks.
What is Rani Therapeutics' stock price target for 2024?: 5 analysts have issued 1-year price targets for Rani Therapeutics' stock. Their RANI share price targets range from $8.00 to $17.00. On average, they anticipate the company's stock price to reach $11.50 in the next twelve months. This suggests a possible upside of 65.0% from the stock's current price.
View analysts price targets for RANI or view top-rated stocks among Wall Street analysts.
How have RANI shares performed in 2024?: Rani Therapeutics' stock was trading at $3.32 at the beginning of the year. Since then, RANI stock has increased by 109.9% and is now trading at $6.97.
View the best growth stocks for 2024 here.
When is Rani Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our RANI earnings forecast.

How were Rani Therapeutics' earnings last quarter?: Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) issued its earnings results on Wednesday, March, 20th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.04.
When did Rani Therapeutics IPO?: Rani Therapeutics (RANI) raised $100 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 6,666,667 shares at a price of $14.00-$16.00 per share.
How do I buy shares of Rani Therapeutics?: Shares of RANI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RANI) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial